Examines prescribing options for rozanolixizumab in generalised myasthenia gravis, suggesting improved patient outcomes.
Aysha Mendes discusses the introduction of rozanolixizumab, which will provide more choice and targeted treatment options for generalised myasthenia gravis, with important considerations for prescribers concerning escalation, delivery and patient outcomes
No takes yet. Share an insight, caveat, or question.
Aysha Mendes (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: